Alendon inhibits osteoclast-mediated bone-resorption. Like all bisphosphonates, it is chemically related to inorganic pyrophosphate, the endogenous regulator of bone turnover. But while pyrophosphate inhibits both osteoclastic bone resorption and the mineralization of the bone newly formed by osteoblasts, alendronate specifically inhibits bone resorption without any effect on mineralization at pharmacologically achievable doses. Its inhibition of bone-resorption is dose-dependent and approximately 1,000 times stronger than the equimolar effect of the first bisphosphonate drug, etidronate. Under therapy, normal bone tissue develops, and alendronate is deposited in the bone-matrix in a pharmacologically inactive form. For optimal action, enough calcium and vitamin D are needed in the body in order to promote normal bone development. Hypocalcemia should, therefore, be corrected before starting therapy.
Alendon is used for the-
- Treatment and prevention of osteoporosis in post-menopausal women
- Treatment of osteoporosis, Alendon increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures)
- Prevention of osteoporosis, Alendon may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture
- Treatment toincrease bone mass in men with osteoporosis
- Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density. Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D
- Treatment of Paget’s disease of bone in men and women
Alendon is also used to associated treatment for these conditions: Osteogenesis Imperfecta (OI), Osteoporosis, Osteoporosis caused by glucocorticoid, Paget’s Disease
|Other Names||ABDP, Acide Alendronique, Acido Alendronico, Acidum Alendronicum, Alendronate, Alendronic acid|
78%. Studies in rats show that plasma protein binding increases with decreasing alendronic acid plasma concentration and increasing pH.
|Therapeutic Class||Bisphosphonate preparations|
|Manufacturer||Beximco Pharmaceuticals Ltd|
|Last Updated:||June 23, 2021 at 11:16 am|
Table Of contents
Treatment of osteoporosis in post-menopausal women: The recommended dose is one Alendon 70 mg once weekly or 10 mg once daily.
Treatment to increase bone mass in men with osteoporosis: The recommended dose is one Alendon tablet 10 mg once daily. Alternatively, one Alendon 70 mg once weekly may be considered.
Prevention of osteoporosis in post-menopausal women: The recommended dose is 35 mg once weekly or 5 mg once daily. The safety of treatment and prevention of osteoporosis with Alendon has been studied for up to 7 years.
Use for elderly patients: No dosage adjustment is required for elderly patients. Because in clinical study there was no evidence of age related differences in the efficacy or safety profiles of Alendon.
Treatment of glucocorticoid-induced osteoporosis in men and women: The recommended dose is 5 mg once daily, except for post-menopausal women not receiving oestrogen, for whom the recommended dose is 10 mg once daily.
Paget’s disease of bone in men and women: The recommended treatment regimen is 40 mg once a day for six months.
The commonest symptomatic side effects are constipation, diarrhoea, oesophageal ulcer, flatulence, dysphagia, musculoskeletal pain, headache, rarely rash, erythema, transient decrease in serum calcium and phosphate, nausea, vomiting, peptic ulceration, hypersensitivity reactions including urticaria and angio-oedema.
The incidence of upper gastrointestinal side effects are increased with the concomitant use of non-steroidal anti-inflammatory agents and aspirin. Absorption of Alendronate is reduced in the presence of antacids and calcium supplements.
- Administer vitamin supplements. Patients may require supplemental vitamin D.
- Avoid multivalent ions. Calcium, antacids, and divalent ions may interfere with the absorption of this medication.
- Take before a meal. Take 30-60 minutes before breakfast.
- Take with a full glass of water.
Volume of Distribution
Due to alendronic acid being incorporated into the skeleton, the terminal half life is estimated to be over 10 years.
Pregnancy & Breastfeeding use
Alendon should not be given to pregnant women or nursing mother.
Hypocalcaemia; Renal impairment; Vitamin D deficiency; Active gastrointestinal problem such as dysphagia, oesophago-duodenitis or ulcer; and Hypersensitivity to any components of the tablet.
Children: Not recommended.